UniProt Q86YV6 · PDB · AlphaFold · Substrate: DAPKtide · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Sunitinib | 99.1% | 0.9% | 91.73 | 0.524 |
| 2 | Vemurafenib | 95.8% | 4.2% | 96.49 | 0.598 |
| 3 | Fedratinib | 79.1% | 20.9% | 96.21 | 0.576 |
| 4 | Pacritinib | 79.0% | 21.1% | 88.64 | 0.452 |
| 5 | Abemaciclib | 67.3% | 32.7% | 91.48 | 0.563 |
| 6 | Abrocitinib | 50.0% | 50.0% | 99.50 | 0.581 |
| 7 | Nintedanib | 44.3% | 55.7% | 90.23 | 0.608 |
| 8 | Midostaurin | 41.4% | 58.6% | 78.64 | 0.500 |
| 9 | Netarsudil | 37.5% | 62.5% | 93.22 | 0.676 |
| 10 | Ponatinib | 35.2% | 64.8% | 78.23 | 0.534 |
| 11 | Selpercatinib | 23.6% | 76.4% | 96.72 | 0.635 |
| 12 | Capmatinib | 19.7% | 80.3% | 99.75 | 0.582 |
| 13 | Crizotinib | 17.7% | 82.3% | 91.39 | 0.581 |
| 14 | Erlotinib | 15.8% | 84.2% | 99.75 | 0.695 |
| 15 | Lenvatinib | 15.7% | 84.3% | 97.74 | 0.726 |
| 16 | Osimertinib | 13.2% | 86.8% | 97.24 | 0.733 |
| 17 | Pirtobrutinib | 12.4% | 87.6% | 99.49 | 0.656 |
| 18 | Apatinib | 12.1% | 87.9% | 97.73 | 0.704 |
| 19 | Neratinib | 11.7% | 88.3% | 93.18 | 0.597 |
| 20 | Alectinib | 11.6% | 88.4% | 95.49 | 0.651 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.32
- Epithelial log2(TPM+1): 0.35
- Fold change: -0.02
- Status: No significant change
High-confidence drugs
- Vemurafenib — inh 95.8% · KISS 38.16
- Sunitinib — inh 99.1% · KISS 33.55
- Fedratinib — inh 79.1% · KISS 18.93
Selectivity landscape vs inhibition on MYLK4
Each point is one of the 92 approved drugs; color = inhibition % on MYLK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…